pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

5,157 catalysts · 4,876 phase readout · 2,347 8k filing · 286 earnings · 275 pdufa · 166 phase 2 completion · 71 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 9 catalysts2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: filing×type: phase readout×type: pdufa×clear all
type
  • phase readout4,876
  • 8k filing2,347
  • earnings286
  • pdufa275
  • phase 2 completion166
  • phase 1 completion71
phase 2 initiation
54
  • phase 1 initiation39
  • phase 1 2 completion33
  • phase 0 trial completion23
  • therapy area
    • Ophthalmology5
    • Dermatology1
    • Infectious Disease1

    Date TBD

    50
    ›TERMINATEDphase readoutNCT05718882: Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC

    Sponsor: RenJi Hospital. Phase: NA. Conditions: Liver Cancer, Hepatocellular Carcinoma, Resistant Cancer

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT00777582: Phase I Comparative Bioavailability Study

    Sponsor: AstraZeneca. Phase: PHASE1. Conditions: Solid Tumors

    full page →ctgov ↗
    ›ENROLLING_BY_INVITATIONphase readoutNCT07442682: Characterisation of a Population of Adults Suffering From Cystic Fibrosis in a Belgian Reference Center

    Sponsor: Erasme University Hospital. Phase: . Conditions: Quality of Lifte, Cystic Fibrosis (CF), Diabetes

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT01580982: Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer

    Sponsor: University of Colorado, Denver. Phase: . Conditions: Lung Neoplasms

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07534059: Impact of Eating Disorders

    Sponsor: University Hospital, Rouen. Phase: . Conditions: Eating Disorders in Adolescence

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06477159: Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency

    Sponsor: Ohio State University. Phase: PHASE4. Conditions: Exocrine Pancreatic Insufficiency

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06385379: Guo's Aortic Arch Reconstruction: A Multicenter, Prospective Study of the Novel WeFlow-Tribranch System (GENIUS Study)

    Sponsor: Hangzhou Endonom Medtech Co., Ltd.. Phase: NA. Conditions: Aortic Arch Aneurysm

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06528080: A Clinical Study for the Treatment of Pediatric and Adolescent Patients With Type 1 Gaucher Disease

    Sponsor: Shanghai Jiao Tong University School of Medicine. Phase: EARLY_PHASE1. Conditions: Gaucher Disease

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07542379: The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer

    Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd.. Phase: EARLY_PHASE1. Conditions: Prostate Cancer

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06295796: A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)

    Sponsor: Merck Sharp & Dohme LLC. Phase: PHASE1. Conditions: Renal Impairment

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07466862: Personalized Cooking and Nutrition Guidance and Physical Activities Program to Reduce Muscle Loss in Advanced Cancer

    Sponsor: Gali Perel. Phase: NA. Conditions: Cancer, Sarcopenia, Muscle Mass Loss

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06446427: The Effect of Acute High Altitude Exposure on Rescuer Performance and Patient Care

    Sponsor: Insel Gruppe AG, University Hospital Bern. Phase: NA. Conditions: High Altitude, Hypobaric Hypoxia, Risk Reduction

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05275686: Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)

    Sponsor: Cedars-Sinai Medical Center. Phase: PHASE2. Conditions: Eustachian Tube Dysfunction

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05380570: Epidemiological Study of Korean Radiation Workers

    Sponsor: Korea Institute of Radiological & Medical Sciences. Phase: . Conditions: Occupational Exposure to Radiation, Neoplasms, Radiation-Induced, Leukemia, Radiation-Induced, Radiation Effects

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07496970: Bilateral Cervical Plexus Block for Postoperative Pain After Thyroidectomy

    Sponsor: University of Gaziantep. Phase: NA. Conditions: Postoperative Pain

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06884670: Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

    Sponsor: The First Affiliated Hospital with Nanjing Medical University. Phase: PHASE2. Conditions: Rectal Cancer

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07015970: Real-life Follow-up of the Physical Activity in Type 1 Diabetes Participants Equipped With an Insulin Pump With Hybrid Closed Loop

    Sponsor: ISIS Diabete Service. Phase: . Conditions: Diabetes Mellitus Type 1, Glucose Metabolism Disorder, Glycemic Control for Diabetes Mellitus, Fear of Hypoglycemia, Treatment Satisfaction, Quality of Life, Hypoglycaemia

    full page →ctgov ↗
    ›WITHDRAWNphase readoutNCT04243473: Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer

    Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Phase: . Conditions: Prostate Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07550673: Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis(UPRISE)

    Sponsor: Xijing Hospital of Digestive Diseases. Phase: PHASE4. Conditions: Acute Severe Ulcerative Colitis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07355673: The Influence of Isolation Techniques in Gingival Irritation During an In-office Bleaching

    Sponsor: University of Santiago de Compostela. Phase: NA. Conditions: Gingival Irritation

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07608341: Influence of Probiotics on Early Gut Microbial Colonization

    Sponsor: BioGaia AB. Phase: NA. Conditions: C-Section

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05234554: The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

    Sponsor: Aldeyra Therapeutics, Inc.. Phase: PHASE3. Conditions: Allergic Conjunctivitis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT02771405: Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC

    Sponsor: National Hepatology & Tropical Medicine Research Institute. Phase: PHASE3. Conditions: Hepatitis C, Chronic, Hepatocellular Carcinoma

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT04291859: Lu AF28996 in Participants With Parkinson's Disease (PD)

    Sponsor: H. Lundbeck A/S. Phase: PHASE1. Conditions: Parkinson Disease

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT06951880: A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers

    Sponsor: AstraZeneca. Phase: PHASE1. Conditions: Healthy Participants

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07483827: A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy

    Sponsor: eleva GmbH. Phase: PHASE1. Conditions: C3 Glomerulopathy (C3G), Healthy Adult Participants

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06888427: Sleep Longitudinal Exploration of the Experience of Patients

    Sponsor: Centre Hospitalier Universitaire de Nice. Phase: . Conditions: Sleep

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04641442: Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

    Sponsor: Novartis Pharmaceuticals. Phase: PHASE2. Conditions: NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT02642042: Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

    Sponsor: National Cancer Institute (NCI). Phase: PHASE2. Conditions: KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07370870: Is Cryotherapy Beneficial After Surgical Removal of Impacted Lower Third Molars?

    Sponsor: Henrique Tedesco. Phase: NA. Conditions: Cold Therapy

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03265262: The Basophil Activation Test as a Diagnostic Tool in Pediatric Food Allergy

    Sponsor: Assistance Publique Hopitaux De Marseille. Phase: NA. Conditions: FOOD ALLERGY

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06572046: STOP-HSP.Net: a Registry for Hereditary Spastic Paraplegia as an Integration Tool for Future Therapeutic Strategies

    Sponsor: IRCCS Fondazione Stella Maris. Phase: . Conditions: Hereditary Spastic Paraplegia

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07368946: Phosphate Assessment in Chronic Kidney Disease Patients Study

    Sponsor: University of Texas Southwestern Medical Center. Phase: NA. Conditions: Chronic Kidney Disease (Stage 3-4), Chronic Kidney Disease Mineral and Bone Disorder

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT07343427: Impact of GON PRF on Central Sensitization in Migraine Patients

    Sponsor: Ankara City Hospital Bilkent. Phase: NA. Conditions: Migraine, Central Sensitization

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06150027: Efficacy of a Systematic Referral to Palliative Care of Patients Who Need for Palliative Care During an Unscheduled Visit in Comprehensive Anticancer Centers

    Sponsor: Centre Leon Berard. Phase: NA. Conditions: Cancer, Emergencies

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05043870: Combined Immunosuppression for Pediatric Crohn's Disease

    Sponsor: Children's Hospital of Fudan University. Phase: PHASE4. Conditions: Crohn Disease, Infliximab, Immunosuppression, Children, Only

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07573670: A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia

    Sponsor: The First Affiliated Hospital of Soochow University. Phase: PHASE2. Conditions: Newly Diagnosed Mixed Phenotype Acute Leukemia

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07607470: Large Algorithm Setting and Validation Study

    Sponsor: Nanopath, Inc. Phase: . Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Infections, Vaginitis, Vaginal Diseases, Genital Diseases, Female, Female Urogenital Diseases, Urogenital Disease, Candidiasis, Mycoses, Vulvovaginitis, Vulvar Diseases, Vaginosis, Bacterial

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07030673: Early Discontinuation of Antibiotic Therapy in Elderly Patients Hospitalized for a Viral Infection

    Sponsor: Centre Hospitalier Universitaire, Amiens. Phase: NA. Conditions: Elderly, Antibiotics Overuse, Viral Infections, PCR Multiplex

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT04232969: Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease

    Sponsor: University College, London. Phase: PHASE3. Conditions: Parkinson's Disease

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06748469: Efficacy of Pulse Radiofrequency Durations in Lumbosacral Pain

    Sponsor: Ankara City Hospital Bilkent. Phase: . Conditions: RADICULAR PAIN

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07367269: Effect of Mandala Coloring on Anxiety, Distress, and Comfort in Breast Cancer Patients Receiving Outpatient Chemotherapy

    Sponsor: Artvin Coruh University. Phase: NA. Conditions: Breast Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07209683: The Effect of Near-infrared Light Therapy on Brain Function and Cognition in Young and Older Adults

    Sponsor: University of Oklahoma. Phase: NA. Conditions: Cognition, Neurovascular Coupling Mechanism and Cognitive Function, Neurovascular Control, Brain Aging, Brain Activity

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07578454: VRehab-SMA Phase 1.2

    Sponsor: University of Oxford. Phase: NA. Conditions: Spinal Muscular Atrophy (SMA)

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05338905: Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT Trial

    Sponsor: Roswell Park Cancer Institute. Phase: NA. Conditions: Head and Neck Squamous Cell Carcinoma

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT02313194: Spinal Cord Neuromodulation for Spinal Cord Injury

    Sponsor: University of California, Los Angeles. Phase: PHASE1. Conditions: Cervical Spinal Cord Injury, Tetraparesis, Tetraplegia

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07323056: Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

    Sponsor: Shanghai Pulmonary Hospital, Shanghai, China. Phase: PHASE2. Conditions: EGFR-mutant Non-small Cell Lung Cancer, Potentially Resectable

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04703322: A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

    Sponsor: Daiichi Sankyo Co., Ltd.. Phase: PHASE2. Conditions: Tenosynovial Giant Cell Tumor

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07597122: MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK

    Sponsor: Insel Gruppe AG, University Hospital Bern. Phase: . Conditions: Sepsis and Septic Shock

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06731322: Gut, Inflammation and Nutrition in Adult Patients After Fontan Operation

    Sponsor: University Medical Centre Ljubljana. Phase: . Conditions: Fontan Circulation, Fontan Procedure

    full page →ctgov ↗
    ← prev
    page 69 of 104
    next →